mylan

Mylan set to close Meda US manufacturing facility

pharmafile | March 28, 2017 | News story | Manufacturing and Production Meda, Mylan 

Mylan continues to cut away Meda’s US operations to “reduce redundancy” – the latest sees Mylan closing an Illinois-based facility, with 90 jobs lost as a result. The moves comes after Mylan had closed Meda’s US headquarters, in New Jersey, in December of last year, resulting in the jettsion of 94 employees.

Mylan had acquired Meda for $7.2 billion last year and has made moves to integrate the business, suggesting that it would have to cut away 10% of its worldwide workforce, from a total of 35,000 employees.

The employees in question, at the Illinois facility, were engaged in the production of various preparation forms, for example of Soma, Astepro and Geritol. The plant will not be closed immediately, with staff cuts to occur in stages until the planned closure in 2018.

“The decision to close the site comes after a careful assessment of bringing the two businesses together as part of our integration process and is consistent with our ongoing efforts to operate our businesses as efficiently as possible,” Mylan released in a company statement.

The move to streamline its business comes after several large acquisitions on Mylan’s part. As well as acquiring Meda, it purchased topicals-focused specialty and generics business of Renaissance for $1 billion in May 2016 and it had also bought Abbott generics for $5.3 billion back in early 2015. This rapid expansion has meant that it has had chosen to be equally as aggressive with its cutbacks on jobs and facilities.

Ben Hargreaves

Related Content

Pfizer to pay $345 million in EpiPen lawsuit

Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …

800px-mono-embolex_by_danny_s

Mylan reaches agreement with Aspen for their European thrombosis business

Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s …

biogen-idec-tecfidera-dimethyl-fumarate

Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute

The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …

Latest content